Malaysia
Making A Difference
Biocon Sdn. Bhd., Malaysia, is Biocon Biologics’ first overseas manufacturing facility, located in BioXcell, Iskandar Puteri, Johor. It houses end-to-end capabilities to produce human insulin and insulin analogs for global markets.
Set up with over USD 350 million (MYR 1,543.5 million), marking Malaysia’s largest foreign biotech investment.
The 562,000 sq. ft. state-of-the-art facility manufactures drug substance, drug product, and devices.
Malaysia’s first and only biopharmaceutical sterile injectables facility approved by the U.S. FDA and European Medicines Agency (EMA).
Employs over 800 people, making it the largest biotech facility in the country.
Recognized by the Malaysia Book of Records in 2022 as the first and largest integrated insulin manufacturer in Malaysia.
Reducing Malaysia’s Dependency on Imports
As a leading global insulin manufacturer, Biocon Biologics is committed to providing affordable, high-quality insulins in Malaysia. In partnership with the Ministry of Health (MoH), it supports growing diabetes care needs and reduces import reliance.
Since 2016, Biocon has supplied over 100 million insulin cartridges to MoH, benefiting 345,000+ patients, thereby reducing Malaysia’s dependency on imports. A market study shows a 40% drop in insulin prices and a 30% increase in insulinization since its entry.
Beyond insulins, Biocon Biologics also supports cancer care in Malaysia with its biosimilars Trastuzumab and Bevacizumab.
Quality Excellence
The manufacturing facility in Johor is approved by U.S. FDA, EMA, NPRA (Malaysia), TGA (Australia), and ANVISA (Brazil), among several other regulatory agencies. The facility has state-of-the-art R&D, Quality Assurance, Quality Control labs and a very robust Quality Management System, which ensures the quality of products manufactured at the facility.
“Biocon Biologics is a global company with capabilities in the development, manufacture and commercialization of high-quality biosimilars. The company’s existence in Malaysia has involved investments totalling USD350 million and contributed to the country’s export value of USD 560 million.”
Biocon Biologics is a global company with capabilities in the development, manufacture and commercialization of high-quality biosimilars. The company’s existence in Malaysia has involved investments totalling USD350 million and contributed to the country’s export value of USD 560 million.”
Datuk Seri Anwar Ibrahim, Prime Minister of Malaysia
Quote Source: Twitter on January, 2025
Quote Source: Twitter on January, 2025
Mission to Enable Universal Access to Insulins
As a leading global insulin manufacturer, Biocon Biologics is enhancing lives in Malaysia and worldwide with its high-quality, scientifically validated human insulin and analogs. As of FY24, it has supplied 9.2 billion doses (rh-Insulin and Insulin Glargine) globally. Committed to universal insulin access, the company aims to reach ‘one-in-five’ insulin-dependent people with diabetes and is steadily advancing toward this goal.
Capacity Expansion
The manufacturing facility in Johor is approved by U.S. FDA, EMA, NPRA (Malaysia), TGA (Australia), and ANVISA (Brazil), among several other regulatory agencies. The facility has state-of-the-art R&D, Quality Assurance, Quality Control labs and a very robust Quality Management System, which ensures the quality of products manufactured at the facility.
Diverse and Dedicated Workforce
Biocon Biologics employs around 800 professionals in Malaysia across research, manufacturing, and quality control for insulin production. The facility is recognized for high quality standards, powered by a diverse team skilled in biotechnology, engineering, quality assurance, and regulatory affairs.
The company fosters a culture of innovation, inclusion, and continuous improvement, offering mentorship, training, and growth opportunities. Diversity is a key focus, reflected in its multicultural workforce and inclusive hiring practices.
Commitment to Sustainability
In Malaysia, Biocon Biologics embeds responsible and sustainable practices into its daily operations to build a better future for the people and the planet. By efficiently managing energy, water, waste, and biodiversity, the Company minimizes environmental impact and promotes resource conservation. Key sustainability initiatives:
Scaleban technology: supports the Company’s water conservation goals, significantly reducing freshwater intake and advancing Zero Liquid Discharge objectives.
Advanced Solvent recovery processes: efficiently reuses solvents, minimizes the need for fresh input and significantly reduces the carbon footprint.
Rooftop solar panels: generate over 1,000 kWp of renewable energy, reducing around 1.6 tCO₂e emissions monthly and supporting sustainable operations.
Leading the Way in Environmental Stewardship
Biocon Biologics actively promotes employee volunteering in Malaysia through the Biocon Malaysia Volunteer Community (BMVC). Employees are encouraged to participate in activities such as planting saplings, beach clean-ups, mangrove restoration, and feeding the homeless.
Key highlights:
Recognized at the 2024 Sustainability & CSR Malaysia Awards, winning the Company of the Year (Biotechnology Manufacturing) award for their impactful efforts.
Participated in the Desaru Bebas Plastic initiative, supported by the Pengerang Municipal Council, removing over 230 kg of waste from Tanjung Balau shorelines
Under the Malaysia Biologics Woodlands Project, planted over 1,000 trees in collaboration with local authorities.
Committed to responsible and sustainable business practices with a focus on biodiversity and land conservation
To know more about Malaysia’s manufacturing facility, click here.
